Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide.
Excellent balance sheet and fair value.
Share Price & News
How has Allergan's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AGN has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AGN exceeded the US Pharmaceuticals industry which returned 6.1% over the past year.
Return vs Market: AGN exceeded the US Market which returned 18% over the past year.
Price Volatility Vs. Market
How volatile is Allergan's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 months ago | Simply Wall StDid Allergan plc (NYSE:AGN) Insiders Buy Up More Shares?
7 months ago | Simply Wall StAre Insiders Buying Allergan plc (NYSE:AGN) Stock?
8 months ago | Simply Wall StAllergan plc (NYSE:AGN): Financial Strength Analysis
Is Allergan undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AGN ($200.15) is trading below our estimate of fair value ($287.33)
Significantly Below Fair Value: AGN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AGN is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: AGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AGN is good value based on its PB Ratio (1.1x) compared to the US Pharmaceuticals industry average (3.1x).
How is Allergan forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: AGN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AGN's is expected to become profitable in the next 3 years.
Revenue vs Market: AGN's revenue (1.3% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: AGN's revenue (1.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AGN's Return on Equity is forecast to be low in 3 years time (9.9%).
How has Allergan performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AGN is currently unprofitable.
Growing Profit Margin: AGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AGN is unprofitable, and losses have increased over the past 5 years at a rate of -18% per year.
Accelerating Growth: Unable to compare AGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).
Return on Equity
High ROE: AGN has a negative Return on Equity (-9.05%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Allergan's financial position?
Financial Position Analysis
Short Term Liabilities: AGN's short term assets ($11.1B) exceed its short term liabilities ($11.1B).
Long Term Liabilities: AGN's short term assets ($11.1B) do not cover its long term liabilities ($25.4B).
Debt to Equity History and Analysis
Debt Level: AGN's debt to equity ratio (38.9%) is considered satisfactory.
Reducing Debt: AGN's debt to equity ratio has reduced from 55% to 38.9% over the past 5 years.
Inventory Level: AGN has a low level of unsold assets or inventory.
Debt Coverage by Assets: AGN's debt is not covered by short term assets (assets are 0.5x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AGN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AGN is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 24.1% per year.
What is Allergan's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: AGN's dividend (1.48%) is higher than the bottom 25% of dividend payers in the US market (1.45%).
High Dividend: AGN's dividend (1.48%) is low compared to the top 25% of dividend payers in the US market (3.73%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, AGN has been paying a dividend for less than 10 years.
Growing Dividend: AGN's dividend payments have increased, but the company has only paid a dividend for 3 years.
Current Payout to Shareholders
Dividend Coverage: AGN is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: AGN's dividends in 3 years are forecast to be well covered by earnings (17.7% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Brent Saunders (49yo)
Mr. Brenton L. Saunders, also known as Brent, J.D., has been the Chairman of the Board at Allergan plc since October 26, 2016 and also has been its Chief Executive Officer and President since July 1, 2014. ...
CEO Compensation Analysis
Compensation vs Market: Brent's total compensation ($USD6.62M) is below average for companies of similar size in the US market ($USD10.79M).
Compensation vs Earnings: Brent's compensation has been consistent with company performance over the past year.
|Executive VP & CFO||2yrs||US$10.54m||0.0021% $1.4m|
|Executive VP||5.6yrs||US$2.80m||0.0063% $4.1m|
|Executive VP & Chief Commercial Officer||5.6yrs||US$3.71m||0.0036% $2.4m|
|Executive VP and Chief R&D Officer||5.5yrs||US$3.26m||0.0027% $1.8m|
|Executive Vice President of Global Operations||2.2yrs||no data||0.0038% $2.5m|
|Chief Accounting Officer||6.5yrs||no data||0.00084% $553.1k|
|Vice President of Investor Relations & Strategic Initiatives||1.2yrs||no data||no data|
|Executive VP & Chief Communications Officer||4.8yrs||no data||no data|
|Vice President of Sales & Marketing||0yrs||no data||no data|
Experienced Management: AGN's management team is seasoned and experienced (5.5 years average tenure).
|Independent Director||10.7yrs||US$473.87k||0.0053% $3.5m|
|Independent Director||1.7yrs||US$397.91k||0.00058% $381.9k|
|Lead Independent Director||3.3yrs||US$499.87k||0.0084% $5.5m|
|Independent Director||1.8yrs||US$449.87k||0.00031% $204.1k|
|Independent Director||3yrs||US$449.87k||0.00056% $368.8k|
|Independent Director||5.6yrs||US$473.87k||0.0019% $1.2m|
|Independent Director||4.9yrs||US$449.87k||0.0016% $1.1m|
|Independent Director||1.5yrs||US$331.19k||0.00019% $125.1k|
|Independent Director||3.1yrs||US$449.87k||0.00077% $507.0k|
Experienced Board: AGN's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Allergan plc's company bio, employee growth, exchange listings and data sources
- Name: Allergan plc
- Ticker: AGN
- Exchange: NYSE
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$65.850b
- Shares outstanding: 329.00m
- Website: https://www.allergan.com
Number of Employees
- Allergan plc
- Clonshaugh Business and Technology Park
- Co. Dublin
- D17 E400
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AGN||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Feb 1993|
|A60||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 1993|
|AGN N||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Feb 1993|
|0Y7T||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Feb 1993|
|AGN||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH 8 REP 1 COM USD0.0001||AR||ARS||Apr 2019|
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women’s health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has a collaboration, option, and license agreement with Lyndra, Inc.; strategic alliance and option agreement with Editas Medicine, Inc.; and gene therapy research collaboration with The National Institute for Bioprocessing Research and Training. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/22 02:28|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.